ALPL and hypophosphatasia: Over the past few years, a human recombinant TNAP enzyme replacement with a bone-targeting peptide sequence marketed as Asfotase Alfa has begun to rescue patients with severe HPP and improve the quality of life for those with more mild symptoms.